Dupilumab for the treatment of eosinophilic esophagitis: a multicenter real-life experience

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

• Eosinophilic esophagitis (EoE) is a rare chronic immunologic disorder of the esophagus with high rates of recurrence and negative impact on quality of life.
• Dupilumab is a monoclonal antibody against the interleukin-4 receptor shown to be efficacious in a Phase 2 trial in EoE.
• Dupilumab was prescribed for off-label use at standard doses (600 mg at time 0 and then 300 mg weekly for 6 months).
• This observational study compared 17 EoE patients treated for 6 months with dupilumab or local steroid formulations in a real-life setting.
• Dupilumab showed statistically significant reduction in patient-reported outcome scores and endoscopic activity.
• Dupilumab may represent a valid therapeutic option in refractory EoE, improving clinical, endoscopic, and histological activity.